Sabby Management’s Immunic IMUX Stock Holding History

Sabby Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,301	Closed	-$642K	–	142
2020 Q2	$642K	Buy	+5,301	New	+$539K	0.13%	56
2015 Q4	–	Sell	-97	Closed	-$317K	–	345
2015 Q3	$156K	Buy	+97	New	+$485K	0.01%	354

Other funds holding IMUX

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Sabby Management's IMUX Position: Q3 2020 in Review

Sabby Management sold out of Immunic (IMUX) in Q3 2020, closing a stake of 5,301 shares — an estimated $642K sold.

Sabby Management first reported a position in IMUX in Q3 2015 and held it in 2 quarters. The position peaked at $642K in Q2 2020. 66 funds tracked by Wall St. Rank hold IMUX as of Q3 2020.

Sabby Management reported no remaining Immunic position as of Q3 2020 after selling out during the quarter.
Sabby Management sold 5,301 Immunic shares in Q3 2020, an estimated $642K.
Sabby Management first reported a position in Immunic in Q3 2015 and held it in 2 quarters.
Sabby Management's Immunic position peaked at $642K in Q2 2020.
66 funds tracked by Wall St. Rank held Immunic as of Q3 2020.

Based on Sabby Management's 13F filing for Q3 2020, filed 16 Nov 2020.